Can adding radiation to osimertinib tame resistant lung cancer?
NCT ID NCT05089916
First seen Jan 17, 2026 · Last updated Jun 24, 2026 · Updated 23 times
Summary
This phase 2 study tests whether it is safe to continue the targeted drug osimertinib (Tagrisso) while also giving radiation therapy to people with advanced EGFR-positive non-small cell lung cancer that has started to grow in a few spots. About 42 participants will receive both treatments together. The main goal is to check for serious side effects, especially lung and heart problems.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
LMU Klinikum der Universität München
München, 80336, Germany
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Osimertinib (Tagrisso) and radiotherapy
What this could lead to
If successful, this could show that combining osimertinib with targeted radiation is safe and helps control lung cancer that has started to progress.
What could go wrong
This is a small, early-phase study (42 people) focused on safety, not a large trial proving effectiveness. There are known risks like lung inflammation or heart problems from the combination.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.